Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation
APPROVED_FOR_MARKETING
Status
Conditions
- Acute Myeloid Leukemia
- Relapsed Adult AML
- Relapsed Pediatric AML
Interventions
- DRUG: ivosidenib (AG-120)
Sponsor
Agios Pharmaceuticals, Inc.